Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) traded up 0.6% during mid-day trading on Monday . The stock traded as high as $12.8920 and last traded at $12.8920. 157 shares traded hands during trading, a decline of 91% from the average session volume of 1,731 shares. The stock had previously closed at $12.82.
Finch Therapeutics Group Stock Performance
The company’s fifty day simple moving average is $13.63 and its two-hundred day simple moving average is $13.19. The company has a market capitalization of $20.76 million, a price-to-earnings ratio of -1.46 and a beta of 1.17.
About Finch Therapeutics Group
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.
Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Finch Therapeutics Group
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- Elon’s Secret AI Partner?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
